Rosuvastatin: Extended-Interval Dosing

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Pacts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Pacts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@kumc.edu.

Get full access to this article

View all access options for this article.

References

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285(19): 2486–2497.

National Cholesterol Education Program (NCEP) Expert Panel. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). ATP III Update 2004 http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Accessed September 12, 2011.

Metz

C.A.

Lucas

K.H.

Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction. Ann Pharmacother. 2001; 35: 496–500.

Backes

J.M.

Venero

C.V.

Gibson

C.A.

Ruisinger

J.F.

Howard

P.A.

Thompson

P.D.

Moriarty

P.M.

Effectiveness and tolerability of every other day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008; 42: 341–346.

Wongwiwatthananukit

Sansanayudh

Dhummauppakorn

Kitiyadisai

Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia. Ann Pharmacother. 2006; 40: 1917–1923.

Dulay

LaHaye

S.A.

Lahey

K.A.

Day

A.G.

Efficacy of alternate day versus daily dosing of rosuvastatin. Can J Cardiol. 2009; 25(2): e28–e31.

Ruisinger

J.F.

Backes

J.M.

Gibson

C.A.

Moriarty

P.M.

Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol. 2009; 103: 393–394.

Backes

J.M.

Moriarty

P.M.

Ruisinger

J.F.

Gibson

C.A.

Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol. 2007; 100: 554–555.

Gadarla

Kearns

A.K.

Thompson

P.D.

Efficacy of rosuvastatin (5 and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008; 101: 1747–1748.

10.

Mackie

B.D.

Satija

Nell

Miller

Aperling

L.S.

Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol. 2007; 99: 291.